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The Ki-67 antigen is used to evaluate the proliferative activity of breast cancer (BC); however, Ki-67’s role as a prognostic marker in
BC is still undefined. In order to better define the prognostic value of Ki-67/MIB-1, we performed a meta-analysis of studies that
evaluated the impact of Ki-67/MIB-1 on disease-free survival (DFS) and/or on overall survival (OS) in early BC. Sixty-eight studies
were identified and 46 studies including 12155 patients were evaluable for our meta-analysis; 38 studies were evaluable for the
aggregation of results for DFS, and 35 studies for OS. Patients were considered to present positive tumours for the expression of Ki-
67/MIB-1 according to the cut-off points defined by the authors. Ki-67/MIB-1 positivity is associated with higher probability of relapse
in all patients (HR¼1.93 (95% confidence interval (CI): 1.74–2.14); Po0.001), in node-negative patients (HR¼2.31 (95% CI: 1.83–
2.92); Po0.001) and in node-positive patients (HR¼1.59 (95% CI: 1.35–1.87); Po0.001). Furthermore, Ki-67/MIB-1 positivity is
associated with worse survival in all patients (HR¼1.95 (95% CI: 1.70–2.24; Po0.001)), node-negative patients (HR¼2.54 (95% CI:
1.65–3.91); Po0.001) and node-positive patients (HR¼2.33 (95% CI: 1.83–2.95); Po0.001). Our meta-analysis suggests that Ki-67/
MIB-1 positivity confers a higher risk of relapse and a worse survival in patients with early BC.
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The crude incidence of breast cancer (BC) in Europe is 109.8/
100.000 women per year and it is responsible for 38.4 out of
100.000 deaths per women annually (Pestalozzi et al, 2005).
Significant improvements in both disease-free survival (DFS) and
overall survival (OS) have been obtained with the extensive use of
adjuvant systemic therapies (EBCTCG, 2005). In the last few
decades, proliferation markers have been extensively evaluated as
prognostic tools in BC. However, the only prognostic factors
utilised in clinical decision making are some histologic features
(e.g. tumour size, histologic grade, nodal status and lympho-
vascular invasion), hormone receptor status, HER-2 status and age
(Colozza et al, 2005; Hayes, 2005).
Ki-67 is present in all proliferating cells and there is great
interest in its role as a marker of proliferation (Gerdes et al, 1983).
The Ki-67 antibody reacts with a nuclear non-histone protein of
395 KD present in all active phases of the cell cycle except the G0
phase (Cattoretti et al, 1992). MIB-1 is a monoclonal antibody
against recombinant parts of the Ki-67 antigen; a good correlation
exists between Ki-67 and MIB-1 (Cattoretti et al, 1992).
Recently, gene array techniques have revealed the Ki-67 gene’s
role in several ‘proliferation signatures’, showing that a set of genes
with increased expression patterns is correlated with tumour cell
proliferation rates, as assessed by the Ki-67 labelling index (Perou
et al, 1999; Whitfield et al, 2006). Moreover, Ki-67 is one of the 21
prospectively selected genes of the Oncotype DX
TM assay used to
predict the risk of recurrence in a node-negative, tamoxifen-
treated BC population enrolled in the National Surgical Adjuvant
Breast and Bowel Project B-14 (NSABP B-14), as well to predict the
magnitude of chemotherapy benefit in women with node-negative,
estrogen receptor (ER)-positive BC enrolled in the NSABP B20 trial
(Paik et al, 2004, 2006).
Despite the large number of published papers analyzing the
prognostic role of Ki-67 in early BC, it is still not considered as an
established factor to be used in clinical practice, probably because
most of the studies are retrospective and because some uncertainty
remains on the way Ki-67 should be assessed (Eifel et al, 2001;
Goldhirsch et al, 2003; Colozza et al, 2005; Urruticoechea et al,
2005). Therefore, due to the fact that a more convincing
demonstration of the Ki-67 prognostic role, in early BC, would
be of value for initiating further research on the assessment
methods of Ki-67, we performed this literature-based meta-
analysis to better quantify the prognostic impact of Ki-67
expression.
MATERIALS AND METHODS
Publication selection
For this meta-analysis, we selected studies evaluating the relation-
ship between Ki-67/MIB-1 status and prognosis in early BC
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spublished until May 2006. To fulfill our selection criteria, the
studies had to have been published as a full paper in English.
Articles were identified by an electronic PubMed search using the
following keywords: ‘breast cancer’,‘Ki-67’,‘MIB-1’,‘proliferative
index’, ‘proliferative marker’, ‘survival’ and ‘prognostic’. We also
screened references from the relevant literature, including all
the identified studies and reviews. To avoid duplicate data, we
identified articles that included the same cohort of patients by
reviewing interstudy similarity in the country in which the study
was performed, investigators in the study, source of patients,
recruitment period and inclusion criteria. Therefore, when the
authors reported the same patient population in several publica-
tions, only the most recent or complete study was included in this
analysis.
Data extraction
Information was carefully extracted from all publications by three
authors (EA, GC and MP). The following data were collected from
each study: publication date, first author’s last name, antibody and
cut-off used for assessing Ki-67 positivity, distribution of Ki-67
status, follow-up period, treatment, nodal status and data allowing
us to estimate the impact of Ki-67 expression on DFS and/or OS.
We did not define any minimal number of patients to include a
study in our meta-analysis, nor a minimal duration of median
follow-up. The exclusion criteria are described below and were not
driven by the study individual results.
Statistical methods
Ki-67 was considered positive or negative according to the cut-off
values provided by the authors. For the quantitative aggregation of
the survival results, the impact of Ki-67 expression on prognosis
was measured using Hazard Ratio (HR). For each study, this HR
was estimated by a method depending on the results provided in
the original publication. The most accurate method was to retrieve
the estimated HR and its variance using two of the following
parameters: the HR point estimate, the log-rank statistic or its
P-value, and the O–E statistic (difference between numbers of
observed and expected events) or its variance. If those data were
not available, we looked for the total number of events, the number
of patients at risk in each group and the log-rank statistic or its
P-value, to estimate the HR. Finally, if the only useful data were in
the form of graphical representations of the survival distributions,
we extracted from them the survival rates at specified time-points
in order to reconstruct the HR estimate and its variance, with the
assumption that the rate of patients censored was constant during
the study follow-up (Parmar et al, 1998).
Three independent persons read the curves to reduce reading
variability. If authors reported survival of three or more groups,
we pooled the results to make feasible a comparison between two
groups. Whenever possible, HR estimates for subgroups were
calculated, such as in node-negative, node-positive or untreated
patients. Results were crosschecked with those from the original
publication to be sure that they are not discrepant, in particular
when reading of the survival rates had to be performed on the
survival curves.
The individual HR estimates were combined into an overall HR
using the Peto’s method that was first used and published in 1985
(Yusuf et al, 1985). We carried out heterogeneity w
2-tests, and if the
assumption of homogeneity of individual HRs had to be rejected,
we used a random-effect model in place of a fixed-effect model. By
convention, an observed HR41 implied a worse prognosis for the
group with positive Ki-67 expression. This impact of Ki-67 on
survival was considered to be statistically significant if the 95%
confidence interval (CI) for the overall HR did not overlap 1. We
have used the authors’ definitions for DFS and OS.
All the statistical calculations for our meta-analysis were
performed with personal computing.
RESULTS
Characteristics of the studies
Out of 68 studies published between the years 1989 and 2006, 46
had the sufficient information for HR extraction, including 38
studies evaluable for DFS and 35 for OS, some of them being
evaluable for only one of these end points, or they analysed only
one of these end points. Tables 1 and 2 list the evaluable studies
with their main characteristics, and Table 3 presents the main
results of this meta-analysis. The reasons to consider an article as
non-evaluable were: (a) no univariate analysis reported; (b) no
possibility to calculate HR using one of the methods mentioned
above due to the fact that the distribution of Ki-67 was not
reported in the article, or sometimes Ki-67 was analysed in
combination with other prognostic markers rendering the analysis
impossible; (c) overlapping data published in different journals;
and (d) inclusion of metastatic BC patients. Table 4 lists all the
studies considered non-evaluable for this meta-analysis, but used
at sensitivity analysis.
The number of patients included across all studies varied from
42 to 863, and the follow-up period varied from 23.6 months
(mean) to 16.3 years (median). Different antibodies were used
through all trials: anti-Ki-67 was used in 24 studies (52.1%), anti-
MIB-1 in 24 studies (52.1%), both antibodies were performed in
five studies (Keshgegian and Cnaan, 1995; Veronese et al, 1995;
Bevilacqua et al, 1996; Querzoli et al, 1996; Billgren et al, 2002),
anti-Ki-S5 in two studies (Rudolph et al, 1999a; Esteva et al, 2004)
and anti-Ki-S11 in one study (Rudolph et al, 1999b). The different
cut-off values used were those of the authors (range: 3.5–34%).
Threshold definitions were mean or median values, the best cut-off
value or an established arbitrary value.
Out of the 38 evaluable studies for DFS (10954 patients),
subgroup analysis was possible in 15 studies with node-negative
patients (3370 patients) (Sahin et al, 1991; Weikel et al, 1991, 1995;
Gaglia et al, 1993; Bevilacqua et al, 1996; Brown et al, 1996; Pierga
et al, 1996; Railo et al, 1997; Jansen et al, 1998; Clahsen et al, 1999;
Harbeck et al, 1999; Rudolph et al, 1999a; Billgren et al, 2002;
Trihia et al, 2003; Erdem et al, 2005), in eight with node-positive
patients (1430 patients) (Weikel et al, 1991, 1995; Gaglia et al, 1993;
Pierga et al, 1996; Jansen et al, 1998; Billgren et al, 2002; Trihia
et al, 2003; Esteva et al, 2004) and in six with untreated node-
negative patients (736 patients) (Sahin et al, 1991; Weikel et al,
1991; Bevilacqua et al, 1996; Railo et al, 1997; Jansen et al, 1998;
Harbeck et al, 1999). Regarding OS (9472 patients), of all 35
studies, subgroup analysis was possible in nine studies with node-
negative patients (1996 patients) (Jensen et al, 1995; Weikel et al,
1995; Bevilacqua et al, 1996; Brown et al, 1996; Domagala et al,
1996; Fresno et al, 1997; Rudolph et al, 1999a; Trihia et al, 2003;
Erdem et al, 2005), in four with node-positive patients (857
patients) (Weikel et al, 1995; Domagala et al, 1996; Gonzalez et al,
2003; Trihia et al, 2003) and in two that included only untreated
patients (node-negative and node-positive) (284 patients) (Pinder
et al, 1995; Bevilacqua et al, 1996).
Meta-analysis
The main meta-analyses results (overall population and DFS/OS)
are shown in Figures 1 and 2. For the overall population, worse
DFS (HR 1.93, 95% CI 1.74–2.14; Po0.001) and OS (HR 1.95, 95%
CI 1.70–2.24; Po0.001) were observed among patients considered
as Ki-67 positive. Worse prognosis was observed independently
both in node-negative (DFS (HR 2.31, 95% CI 1.83–2.92;
Po0.001); OS (HR 2.54, 95% CI 1.65–3.91; Po0.001)) and in
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snode-positive patients (DFS (HR 1.59, 95% CI 1.35–1.87;
Po0.001); OS (HR 2.33, 95% CI 1.83–2.95; Po0.001)). For the
untreated patients subgroup analysis, worse DFS was found in all
node-negative patients (HR 2.72, 95% CI 1.97–3.75; Po0.001), as
well as worse OS in node-negative and node-positive patients taken
together (HR1.79, 95% CI 1.22–2.63; P¼0.001).
The necessity to exclude some studies due to a lack of results
for aggregating the results is a well-known important problem
when conducting a meta-analysis, because the excluded studies
show often a smaller effect compared to the studies published
with full details and evaluable for the meta-analysis. To assess
the impact of bias related to the unevaluable studies (that might
lead to an overestimation of the effect), we performed an analy-
sis on the overall patient populations including both evaluable
and unevaluable studies. For papers reporting only HR esti-
mates obtained in multivariate analyses, we used this HR estimate
together with its variance. For those with uncertainties related
to the number of events and then the variance of the HR
estimate, we made rough approximation of the variance. Finally,
for the studies where no useful information could be retrieved
from the publication, we considered that the HR estimate was
1 (i.e. no impact at all for Ki-67) and used a minimal variance
compared to the included studies of the same size. Even
by carrying out this sensitivity analysis, we still observe a
significant pejorative impact of Ki-67 positivity on DFS (HR
1.74, 95% CI 1.56–1.95; Po0.001; heterogeneity test Po0.001)
and OS (HR 1.76, 95% CI 1.54–2.00; Po0.001; heterogeneity
test Po0.001).
Table 1 Main characteristics of all studies included in the meta-analysis for overall survival
Author
Patients Ki-
67+/  (total)
Median FU
(mos)
Systemic
treatment Antibody
Threshold
(chosen by) HR (95% CI)
Bevilacqua et al (1996) 94/13 (107) 74 Untreated Anti-Ki-67
Anti-MIB-1
10% (arbitrary) 2.75 (1.02–7.39)
Bos et al (2003) 63/87 (150) 106 (mean) NX4: CMF or TAM Anti-Ki-67 10% (arbitrary) 2.47 (1.08–5.65)
Brown et al (1996) 170/504 (674) 72 156 CT and/or HT Anti-Ki-67 5% (optimal cut-off) 1.19 (0.79–1.80)
Caly et al (2004) 122/122 (244) 72 (minimum) Not reported Anti-MIB-1 32% (proportion of
scored cells)
1.95 (0.92–4.14)
Domagala et al (1996) N0 66/45 (111) 88 47 CT or HT Anti-MIB-1 10% (median value) 3.04 (1.03–8.99)
Domagala et al (1996) N+ 40/35 (75) 88 47 CT or HT Anti-MIB-1 10% (median value) 1.38 (0.66–2.86)
Erdem et al (2005) 13/34 (47) 72.5 All adjuvant CT (?) Anti-Ki-67 10% (median value) 17.23 (2.42–122.36)
Fresno et al (1997) 84/62 (146) 75 13 CMF 80 TAM Anti-MIB-1 10% (arbitrary) 1.81 (0.71–4.59)
Gasparini et al (1994) 83/82 (165) 60 82 CMF and/or HT Anti-Ki-67 7.5% (mean value) 2.58 (1.21–5.49)
Gonzalez et al (2003) NR (221) 102.5 Not reported Anti- MIB-1 30% (arbitrary) 3.18 (1.52–6.65)
Goodson et al (2000) 56/56 (112) 5.1y 104 CT or HT Anti- MIB-1 24% (mean value) 2.90 (1.18–7.15)
Heatley et al (2002) 26/33 (59) 5y Not reported Anti-Ki-67 10% (mean value) 0.81 (0.36–1.81)
Hlupic et al (2004) 117/75 (192) 180 (for
N+ patients)
Various adjuvant CT
regimens (?)
Anti-Ki-67 10% (arbitrary) 1.30 (0.80–2.11)
Jacquemier et al (1998) 74/78 (152) 60 (?) FAC, FEC or FMC Anti- MIB-1 3.5% (median value) 3.29 (1.49–7.22)
Jansen et al (1998) 153/168 (321) 128 (?) FAC Anti-MIB-1 7% (median value) 1.35 (1.01–1.80)
Jensen et al (1995) 54/64 (118) 104 3 CT or HT Anti-MIB-1 17% (median value) 3.41 (1.44–8.06)
Liu et al (2001) 389/384 (773) 16.3y 268 CT (17% DOX) Anti-MIB-1 17.8% (median value) 1.76 (1.41–2.20)
Locker et al (1992) 23/44 (67) 27 Not reported Anti-Ki-67 9% (tertile distribution) 4.19 (1.19–14.7)
Mottolese et al (2000) 87/70 (157) 60 All EC Anti-Ki-67 10% (arbitrary) 1.82 (0.90–3.67)
Pellikainen et al (2003) 184/230 (414) 57.2 (?) CMF and TAM or
toremifene
Anti-MIB-1 20% (arbitrary) 2.56 (1.46–4.50)
Pierga et al (1996) 66/70 (136) 70 16 FAC/39 TAM Anti-Ki-67 8% (median value) 1.37 (0.64–2.91)
Pietilainen et al (1996) 100/88 (188) 8.6y (mean) 64 CT (?) Anti-MIB-1 20% (arbitrary) 1.88 (1.16–3.05)
Pinder et al (1995) 74/103 (177) NR Untreated Anti-MIB-1 34% (tertile
distribution)
1.66 (1.09–2.52)
Pinto et al (2001) 136/159 (295) 39.6 201 CT/131 HT Anti-Ki-67 10% (arbitrary) 1.46 (0.74–2.87)
Querzoli et al (1996) 43/127 (170) 66.5 Not reported Anti-Ki-67
Anti-MIB-1
13% (tertile
distribution)
2.05 (1.11–3.77)
Railo et al (1993) 37/289 (326) 2.7y (mean) Not reported Anti-Ki-67 10% (nuclear staining) 2.39 (0.77–7.38)
Rudolph et al (1999a) 363/500 (863) 149.3 531 CT or HT Anti-Ki-S11 25% (median values) 1.91 (1.50–2.44)
Rudolph et al (1999b) 137/234 (371) 95 86 TAM Anti-Ki-S5 25% (median values) 4.88 (2.98–7.99)
Seshadri et al (1996) 235/472 (707) 66 (?) CMF or TAM Anti-MIB-1 10% (arbitrary) 2.60 (1.80–3.75)
Thor et al (1999) 243/243 (486) 62 Not reported Anti-MIB-1 28.6% (median value) 1.94 (1.04–3.61)
Trihia et al (2003) N0 61/127 (188) 13.5y 125 CMF Anti-MIB-1 16% (proportion of
scored cells)
1.90 (1.18–3.08)
Trihia et al (2003) N+ 82/164 (246) 13.5y 246 CMF Anti-MIB-1 16% (proportion of
scored cells)
2.42 (1.71–3.41)
Tynninen et al (1999) 42/42 (84) 10.3y (mean) 13 CT (?) Anti-MIB-1 9.8% (median value) 1.05 (0.55–2.00)
Veronese et al (1995) 64/63 (127) 61 Not reported Anti-Ki-67
Anti-MIB-1
14% (median value) 0.42 (0.20–0.87)
Weikel et al (1991) 78/115 (193) 23.6 (mean) CMF and/or TAM Anti-Ki-67 20% (proportion of
scored cells)
3.42 (1.39–8.40)
Weikel et al (1995) N0 93/141 (234) 3.4y (mean) Mostly TAM Anti-Ki-67 20% (groups) 1.66 (0.79–3.51)
Weikel et al (1995) N+ 138/177 (315) 3.4y (mean) 315 CMF and/or TAM Anti-Ki-67 20% (groups) 2.36 (1.55–3.60)
Wintzer et al (1991) 32/31 (63) 37 Not reported Anti-Ki-67 12% (median value) 2.51 (1.00–6.34)
CI, confidence interval; CMF, cyclophosphamide, methotrexate, 5-fluorouracil; CT, chemotherapy; DOX, doxorubicin; EC, epirubicin, cyclophosphamide; FAC, 5-fluorouracil,
doxorubicin, cyclophosphamide; FEC, 5-fluorouracil, epirubicin, cyclophosphamide; FMC, 5-fluorouracil, mitoxantrone, cyclophosphamide; FU, follow-up; HR, hazard ratio; HT,
hormonotherapy; mos, months; N0, node-negative; N+, node-positive; NR, not reported; TAM, tamoxifen; +, positive;  , negative; y, years.
Ki-67 in early breast cancer
E de Azambuja et al
1506
British Journal of Cancer (2007) 96(10), 1504–1513 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sDISCUSSION
The present meta-analysis confirms that high Ki-67 expression in
patients with early BC confers worse prognosis in the overall
population and quantifies its prognostic univariate impact.
Further, it was also shown in subgroup analyses for node-negative,
node-positive and untreated patients. This is the first meta-
analysis of published studies to evaluate the association between
Table 2 Main characteristics of all studies included in the meta-analysis for disease-free survival
Author
Patients
Ki-677 (total)
Median FU
(mos)
Systemic
Treatment Antibody
Threshold
(chosen by) HR (95% CI)
Bevilacqua et al (1996) 13/94 (107) 74 Untreated Anti-Ki-67
Anti-MIB-1
10% (arbitrary) 3.95 (1.45–10.7)
Billgren et al (2002) N0 189/241(430) 5.7y 149 CMF/484 TAM* Anti-Ki-67
Anti-MIB-1
15% (arbitrary) 2.18 (1.04–4.57)
Billgren et al (2002) N+ 168/134 (302) 5.7y 149 CMF/484 TAM* Anti-Ki-67
Anti-MIB-1
15% (arbitrary) 2.20 (1.28–3.78)
Bos et al (2003) 63/87 (150) 106 (mean) NZ4: CMF or TAM Anti-Ki-67 10% (arbitrary) 1.59 (0.83–3.04)
Bouzubar et al (1989) 65/59 (124) 3 (minimum) Not reported Anti-Ki-67 20% (arbitrary) 2.07 (0.99–4.30)
Brown et al (1996) 170/504 (674) 72 156 CT and/or HT Anti-Ki-67 5% (optimal cut-off) 1.71 (1.18–2.47)
Caly et al (2004) 122/122 (244) 72 (minimum) Not reported Anti-MIB-1 32% (proportion of
scored cells)
1.61 (1.01–2.55)
Clahsen et al (1999) 215/217 (430) 41 FAC (all)/ CMF for N+ Anti MIB-1 20% (arbitrary) 2.84 (1.80–4.47)
Erdem et al (2005) 13/34 (47) 72.5 All adjuvant CT (?) Anti-Ki-67 10% (median value) 6.96 (2.62–18.44)
Esteva et al (2004) 29/61 (100) 11y FAC Anti-Ki-S5 12% (proportion of
scored cells)
1.42 (0.75–2.66)
Gaglia et al (1993) N0 90/90 (180) 31 (mean) 158 TAM Anti-Ki-67 9% (median value) 4.60 (1.58–13.38)
Gaglia et al (1993) N+ 87/86 (173) 31 (mean) 70 CMF /138 TAM Anti-Ki-67 9% (median value) 1.87 (0.94–3.70)
Gasparini et al (1994) 83/82 (165) 60 82 CMF and/or HT Anti-Ki-67 7.5% (median value) 3.21 (1.53–6.75)
Goodson et al (2000) 56/56 (112) 5.1y 104 CT or HT Anti-MIB-1 24% (mean value) 2.06 (0.95–4.45)
Harbeck et al (1999) 20/96 (116) 76 Untreated Anti-Ki-67 25% (optimised values) 2.69 (1.09–6.62)
Jacquemier et al (1998) 74/78 (152) 60 (?) FAC, FEC or FMC Anti-MIB-1 3.5% (median value) 2.81 (1.53–5.17)
Jansen et al (1998) N0 72/111 (183) 128 Untreated Anti-MIB-1 7% (median value) 2.52 (1.50–4.22)
Jansen et al (1998) N+ 81/57 (138) 128 (?) FAC Anti-MIB-1 7% (median value) 1.34 (0.89–2.04)
Keshgegian and Cnaan
(1995)
66/65 (131) Up to 46 mos Not reported Anti-Ki-67
Anti-MIB-1
10% (arbitrary) 1.44 (0.50–4.10)
Lau et al (2001) 22/75 (97) 64 (mean) Various adjuvant CT
Regimens (?)
Anti-MIB-1 25% (arbitrary) 4.10 (1.33–12.55)
Liu et al (2001) 389/384 (773) 16.3y 268 CT (17% DOX) Anti-MIB-1 17.8% (median value) 1.69 (1.39–2.06)
Locker et al (1992) 23/44 (67) 27 Not reported Anti-Ki-67 9% (tertile distribution) 2.04 (0.83–5.03)
Michalides et al (2002) 226/126 (352) 48y Mostly TAM Anti-MIB-1 5% (arbitrary) 2.06 (1.28–3.33)
Mottolese et al (2000) 87/70 (157) 60 All EC Anti-Ki-67 10% (arbitrary) 1.52 (0.82–2.81)
Pellikainen et al (2003) 184/230 (414) 57.2 (?) CMF and TAM or
toremifene
Anti-MIB-1 20% (arbitrary) 2.14 (1.36–3.38)
Pierga et al (1996) N0 30/48 (78) 70 Not reported Anti-Ki-67 8% (median value) 1.89 (0.78–4.54)
Pierga et al (1996) N+ 36/22 (58) 70 16 FAC/39 TAM Anti-Ki-67 8% (median value) 0.95 (0.37–2.43)
Pietilainen et al (1996) 97/82 (179) 8.6 (mean) 64 CT (?) Anti-MIB-1 20% (arbitrary) 1.60 (1.01–2.53)
Pinto et al (2001) 136/159 (295) 39.6 201 CT/131 HT Anti-Ki-67 10% (arbitrary) 1.61 (0.93–2.80)
Querzoli et al (1996) 43/127 (170) 66.5 Not reported Anti-Ki-67
Anti-MIB-1
13% (tertile distribution) 2.20 (1.25–3.87)
Railo et al (1993) 37/289 (326) 2.7y (mean) Not reported Anti-Ki-67 10% (proportion of
scored cells
3.38 (1.61–7.12)
Railo et al (1997) 89/123 (212) 8.3y (mean) Untreated Anti-Ki-67 10% (arbitrary) 2.46 (1.33–4.56)
Rudolph et al (1999a) 363/500 (863) 149.3 531 CT or HT Anti-Ki-S11 25% (median values) 1.98 (1.56–2.52)
Rudolph et al (1999b) 137/234 (371) 95 86 TAM Anti-Ki-S5 25% (median values) 2.96 (1.92–4.57)
Sahin et al (1991) 14/28 (42) 88 Untreated Anti-Ki-67 12% (3 groups) 4.54 (1.37–15.03)
Seshadri et al (1996) 235/472 (707) 66 (?) CMF or TAM Anti-MIB-1 10% (arbitrary) 2.10 (1.50–2.93)
Thor et al (1999) 243/243 (486) 62 Not reported Anti-MIB-1 28.6% (median value) 2.19 (1.45–3.30)
Trihia et al (2003) N0 61/127 (187) 13.5y 125 CMF Anti-MIB-1 16% (proportion of
scored cells)
1.20 (0.78–1.84)
Trihia et al (2003) N+ 82/164 (246) 13.5y 246 CMF Anti-MIB-1 16% (proportion of
scored cells)
1.80 (1.31–2.47)
Veronese et al (1995) 64/63 (127) 61 Not reported Anti-Ki-67
Anti-MIB-1
14% (median value) 0.60 (0.33–1.10)
Weikel et al (1991) N0 34/42 (76) 23.6 (mean) Untreated Anti-Ki-67 20% (proportion of
scored cells)
1.75 (0.34–9.01)
Weikel et al (1991) N+ 43/65 (108) 23.6 (mean) CMF and/or TAM Anti-Ki-67 20% (proportion of
scored cells
0.71 (0.09–5.36)
Weikel et al (1995) N0 93/141 (234) 3.4y (mean) Mostly TAM Anti-Ki-67 20% (groups) 1.10 (0.53–2.28)
Weikel et al (1995) N+ 138/177 (315) 3.4y (mean) 315 CMF and/or TAM Anti-Ki-67 20% (groups) 1.51 (1.13–2.00)
Wintzer et al (1991) 32/31 (63) 37 Not reported Anti-Ki-67 12% (median value) 2.99 (1.30–6.92)
CI, confidence interval; CMF, cyclophosphamide, methotrexate, 5-fluorouracil; CT, chemotherapy; DOX, doxorubicin; EC, epirubicin, cyclophosphamide; FAC, 5-fluorouracil,
doxorubicin, cyclophosphamide; FEC, 5-fluorouracil, epirubicin, cyclophosphamide; FMC, 5-fluorouracil, mitoxantrone, cyclophosphamide; FU, follow-up; HR, hazard ratio; mos,
months; N0, node-negative; N+, node-positive; NR, not reported; TAM, tamoxifen; y, years; +, positive;  , negative. *For total population (n¼732).
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markers may be defined as those markers that are associated with
some clinical outcomes, typically a time-to-event outcome such as
OS or DFS, independently of any treatment or intervention. The
best setting to apply this concept is in untreated populations,
which helps identifying the so-called pure prognostic marker.
Prognostic markers may also be used to aid the decision-making
process for adjuvant therapy, for example, they may be used as
decision aids in determining whether a patient should receive
adjuvant chemotherapy or how aggressive that therapy should be
(McShane et al, 2005).
Ki-67 has been assayed in many studies as a prognostic and/or
predictive marker in early BC. As a predictive marker, very few
trials of primary systemic therapy, mostly retrospective and with
conflicting results have been published (Colozza et al, 2005), and
therefore we felt that the assessment of the predictive role of Ki-67
was out of scope for this meta-analysis.
Our meta-analysis was carried out using literature published
results, and we therefore acknowledge some limitations of our
approach which is, however, much less expensive than a meta-
analysis using individual patients data. The language selection
could favour positive studies, following the assumption that they
are more often published in English, whereas the negative ones
tend to be published more often in local journals using the author’s
native languages (Egger et al, 1997). However, we did not identify
many papers published in a national language (Italian, Russian,
Serbian, German) (Lelle, 1990; Topic et al, 2002; Kushlinskii et al,
2004; Costarelli et al, 2005). This may be called the ‘Tower of Babel
bias’ and, in at least one of 36 consecutive meta-analyses, the
exclusion of papers for linguistic reasons produced different
results from those which would have been obtained if this
exclusion criterion had not been used (Gregoire et al, 1995).
Another possible source of confusion is the use of the same cohort
of patients in different publications, although studies that were
clearly based on the analysis of the same patient cohorts were
excluded in this meta-analysis.
Some authors consider meta-analyses using individual data to
be the gold standard evidence (Stewart and Parmar, 1993; Oxman
et al, 1995). This approach is normally considered to be a new
study that takes into account all performed studies on the topic,
published or not, and that requires an individual data update by
the investigators; it is thus much more time consuming, complex
and costly. In a comparison between a meta-analysis based on
individual patient data and one based on extracted data, the overall
duration for the former was found to be 1–5 years while for the
latter it is only 1–5 months. Additionally, the overall cost to
perform an individual patient data meta-analysis is $50000 to
$500000, whereas for an extracted data study it is in the range
of $5000 to $30000 (Piedbois and Buyse, 2004). Therefore, a meta-
analysis on published literature is worthwhile and, especially in a
situation, as here, it is very unlikely to find the resources to
conduct a meta-analysis based on the individual data.
The method used for extrapolating HR might be a source of
some variability in the HR estimates. When no other useful
information was available, we extrapolated the HR from the
survival curves using several time points during follow-up for
reading the corresponding survival rates, assuming that censored
observations were uniformly distributed. The estimation of
survival rates based on the graphical representation of the survival
curves was performed independently by three of the authors and
we compared our HR estimate and its statistical significance with
the results published in each individual trial. We did not identify
any major contradiction between our results and the results
available in the papers.
The adverse impact of Ki-67 positivity on both OS and DFS was
observed in the overall population as well as in the subgroups
node-negative and node-positive patients. Significant hetero-
geneity was detected when considering the whole population and
node-negative patients. It is not considered appropriate to define a
single measure (i.e. HR associated with Ki-67 positivity in this
case) from studies with inherent dissimilarities. The observed
disparity among the conclusions of different studies, responsible
for the observed heterogeneity, can be quantified by applying
Table 3 HR values and heterogeneity test for all subgroups analysis in patients with early breast cancer
Group Number of studies Number of patients
Fixed effect HR
(95% CI)
Heterogeneity test
(P-value)
Random effect HR
(95% CI)
Disease-free survival
All pts 38 10954 1.88 (1.75–2.02) 0.01 1.93 (1.74–2.14)
N  pts 15 3370 2.20 (1.88–2.58) 0.03 2.31 (1.83–2.92)
N+ pts 8 1430 1.59 (1.35–1.87) 0.68
N  untreated pts 6 736 2.72 (1.97–3.75) 0.89
Overall survival
All pts 35 9472 1.89 (1.74–2.06) o0.001 1.95 (1.70–2.24)
N  pts 9 1996 2.19 (1.76–2.72) 0.001 2.54 (1.65–3.91)
N+ pts 4 857 2.33 (1.83–2.95) 0.44
N /N+ untreated pts 2 284 1.79 (1.22–2.63) 0.36
CI: confidence interval; HR: hazard ratio; N : node-negative; N+: node-positive; pts: patients.
Table 4 Studies that were not evaluable for this meta-analysis, but
included in the sensitivity test
Author
Number of
patients
Ki-67 prognostic
value (Yes/No)
Beck et al (1995) 462 Yes
Biesterfeld et al (1998) 103 Yes
Bukholm et al (2003) 147 No
Ceccarelli et al (2000) 217 Yes
Galiegue et al (2004) 117 No
Gasparini et al (1992) 164 Yes
Haerslev et al (1996) 487 Yes
Jalava et al (2000) 414 No
Kroger et al (2006) 157 No
Kronblad et al (2006) 377 Yes
Lampe et al (1998) 142 Yes
Liu et al (2000) 225 Yes
Michels et al (2003) 104 No
Molino et al (1997) 322 Yes
Rudas et al (1994) 184 No
Tsutsui et al (2005) 249 Yes
Yang et al (2003) 147 No
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squality scores to the selected studies included in the meta-analysis.
However, these scores do not always explain the observed results
(Greenland, 1994). In this case, the methodological characteristics
of each study must be taken into consideration.
In 1992, Cattoretti et al (1992) reported better success in
staining Ki-67 in paraffin-embedded samples after the new
antibodies anti-MIB-1 and anti-MIB-3 had been developed.
Although several antibodies are now commercially available to
stain Ki-67, anti-MIB-1 is the most frequently used in recent
studies (Urruticoechea et al, 2005). In our meta-analysis, antibodies
other than anti-MIB-1 and anti-Ki-67 were included, such as anti-Ki-
S5 (Rudolph et al, 1999a; Esteva et al, 2004) and anti-Ki-S11 (Rudolph
Bevilacqua 1996
Billgren 2002 (NO)
Billgren 2002 (N+)
Bos 2003
Bouzubar 1989
Brown 1996
Caly 2004
Clahsen 1999
Erdem 2005
Esteva 2004
Gaglia 1993 (N+)
Gasparini 1994
Goodson 2000
Harbeck 1999
Jacquemier 1998
Pietiläinen 1996
0.0 2.5 7.5 10.0 5.0
Wintzer 1991
Weikel 1995 (N+)
Weikel 1995 (NO)
Weikel 1991 (N+)
Weikel 1991 (NO)
Veronese 1995
Trihia 2003 (N+)
Trihia 2003 (NO)
Thor 1999
Seshadri 1996
Sahin 1991
Rudolph 1999 II
Rudolph 1999 I
Railo 1993
Railo 1997
Querzoli 1996
Pinto 2001
Pierga 1996 (N+)
Pierga 1996 (NO)
Pellikainen 2003
Mottolese 2000
Michalides 2002
Locker 1992
Liu 2001
Lau 2001
Keshgegian 1995
Jansen 1998 (N+)
Jansen 1998 (NO)
Gaglia 1993 (NO)
Figure 1 Results of the meta-analysis with all evaluable studies for DFS.
A hazard ratio (HR)41 implies a worse DFS for the group with increased
Ki-67. The squared size is proportional to the number of patients included
in each study. The centre of the lozenge gives the combined HR for the
meta-analysis and its extremities the 95% CI.
Bevilacqua 1996
Bos 2003
Domagala 1996 (NO)
Domagala 1996 (N+)
Pietiläinen 1996
Rudolph 1999 II
Wintzer 1991
7.5 10.0 5.0 2.5 0.0
Weikel 1995 (N+)
Weikel 1995 (NO)
Weikel 1991
Veronese 1995
Tyninnen 1999
Trihia 2003 (N+)
Trihia 2003 (NO)
Thor 1999
Seshadri 1996
Rudolph 1999 I
Railo 1993
Querzoli 1996
Pinto 2001
Pinder 1995
Pierga 1996
Pellikainen 2003
Mottolese 2000
Locker 1992
Liu 2001
Jensen 1995
Jansen 1998
Jacquemier 1998
Hlupic 2004
Goodson 2000
Heatley 2002
Gonzalez 2003
Gasparini 1994
Fresno 1997
Erdem 2005
Caly 2004
Brown 1996
Figure 2 Results of the meta-analysis with all evaluable studies for OS. A
HR41 implies a worse OS for the group with increased Ki-67. The
squared size is proportional to the number of patients included in each
study. The centre of the lozenge gives the combined HR for the meta-
analysis and its extremities the 95% CI.
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set al, 1999b), albeit representing only a minority of the cases.
Moreover, Ki-67 expression is usually estimated as the percentage of
tumour cells positively stained by the antibody, with nuclear staining
being the most common criteria of positivity. The use of different
antibodies and scoring protocols without a standard minimum
number of cells to be counted may account for some of the
differences between the studies.
In our meta-analysis, some studies have used 10% as the cut-off
(arbitrary value), whereas others have chosen mean, median, the
optimal cut-off value or arbitrary values, and these differences
might be responsible for the difficulty in determining a standard
threshold in daily practice. However, some authors have described
that the choice of the cut-off point for IHC may depend on the
clinical objective: if Ki-67 is used to exclude patients with slowly
proliferating tumours from chemotherapeutic protocols, a cut-off of
10% will help avoid overtreatment. In contrast, if Ki-67 is used to
identify patients sensitive to chemotherapy protocols, it is preferable
to set the cut-off at 25% (Spyratos et al,2 0 0 2 ) .I nt h ec o n t e x to ft h i s
meta-analysis, we may assume that increased Ki-67 leads to an
increased risk of relapse and/or death and that a relative increase is
estimated although the baseline risk (the risk in the group considered
Ki-67 negative) is not the same in all the studies.
A further limitation of our meta-analysis is that it assesses only
the univariate prognostic value of Ki-67. So, we cannot infer from
our meta-analysis that Ki-67 is an independent factor; the answer
to that question should come from a prospective study (it is likely
that a meta-analysis of individual data would not solve the
question as the intersection of the sets of covariates available in the
individual studies is most probably very small).
To better clarify the prognostic role of ER status, Sotiriou et al
(2006) used gene array profiling to explore the implications of the
joint distribution of ER status and gene expression grade index
(GGI) to predict clinical outcome. They found that almost all
ER-negative tumours were associated with high GGI scores (high
grade), whereas ER-positive tumours were associated with a
heterogeneous mixture of GGI values. This means that GGI adds
additional prognostic information when the ER status is known,
whereas the opposite is not true. Unfortunately, due to the lack of
information in the published studies used in our study, an analysis
of the impact of Ki-67 expression on the ER-negative and
ER-positive subpopulations and grade, which are well-known risk
factor associated with worse outcome, was not possible. Table 5
summarises the main results of the recent genes signatures for
prognosis/prediction in BC.
Despite years of research and hundreds of reports of tumour
markers in oncology, the number of markers that have emerged as
clinically useful is quite small. The REporting of tumour MARKer
Studies (REMARK) guidelines was the major task of the NCI-
EORTC First International Meeting on Cancer Diagnosis, repre-
senting a collaborative effort of statisticians, clinicians and
laboratory scientists. The guidelines contain 20 recommendations
derived from studies on tumour markers and regarding study
design, methods of statistical analysis, preplanned hypotheses,
patient and specimen characteristics, and assay methods. The
widespread use of published guidelines for analytical methods and
the reporting of results would greatly facilitate the development of
alternative analyses and meta-analyses (Alonzo, 2005; McShane
et al, 2005).
Despite some limitations, this meta-analysis supports the
prognostic role of Ki-67 in early BC, by showing a significant
association between its expression and the risk of recurrence and
death in all populations considered and for both outcomes, DFS
and OS. Had the proposed REMARK guidelines been employed in
all the studies selected for this meta-analysis and had all necessary
information been available, our literature-based meta-analysis
would better characterise the role of Ki-67 as prognostic marker.
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